Although this deal is structured to make SNUS the acquiring company, it is a reverse merger inasmuch as OncoGenex is contributing the bulk of the management team and pipeline and will own more than half the equity if milestones are met.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.